SIA
VRTX icon

Schechter Investment Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Schechter Investment Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$1.25M Sell
2,578
-342
-12% -$159K 0.1% 195
2024
Q4 		$1.18M Buy
2,920
+563
+24% +$261K 0.09% 213
2024
Q3 		$1.1M Buy
2,357
+615
+35% +$295K 0.08% 236
2024
Q2 		$817K Buy
1,742
+54
+3% +$23.4K 0.06% 279
2024
Q1 		$706K Buy
1,688
+16
+1% +$6.76K 0.05% 314
2023
Q4 		$680K Buy
1,672
+159
+11% +$58.7K 0.06% 297
2023
Q3 		$526K Buy
1,513
+3
+0.2% +$1.05K 0.05% 331
2023
Q2 		$531K Buy
1,510
+59
+4% +$19.9K 0.05% 375
2023
Q1 		$457K Buy
1,451
+261
+22% +$78.3K 0.04% 431
2022
Q4 		$344K Buy
1,190
+2
+0.2% +$610 0.03% 595
2022
Q3 		$344K Buy
1,188
+447
+60% +$129K 0.03% 647
2022
Q2 		$209K Buy
+741
New +$198K 0.02% 833

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Schechter Investment Advisors's VRTX Position: Q1 2025 in Review

Schechter Investment Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 12% in Q1 2025, selling an estimated $159K and leaving 2,578 shares worth $1.25M. The position accounts for 0.1% of the portfolio, ranked #195.

Schechter Investment Advisors first reported a position in VRTX in Q2 2022 and has held it in 12 quarters since. 1,612 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

  • Schechter Investment Advisors held 2,578 shares of Vertex Pharmaceuticals worth $1.25M as of Q1 2025.
  • Schechter Investment Advisors sold 342 Vertex Pharmaceuticals shares in Q1 2025, an estimated $159K.
  • Vertex Pharmaceuticals made up 0.1% of Schechter Investment Advisors's portfolio in Q1 2025, its #195 holding.
  • Schechter Investment Advisors first reported a position in Vertex Pharmaceuticals in Q2 2022 and has held it in 12 quarters since.
  • 1,612 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on Schechter Investment Advisors's 13F filing for Q1 2025, filed 1 May 2025.